GlassScriptPhysician profile
Alexandra Timmons
NPI 1043997893
$2,625.99
in general payments reported to CMS, 2019-2025
31 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $550 · 2024: $1,574 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $417.01 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $287.45 | 2023-2025 | |
| Novo Nordisk INC | $260.66 | 2023-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $216.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $161.96 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $155.80 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.69 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $110.79 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $99.61 | 2023 | |
| Mylan Specialty L.P. | $98.33 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $95.57 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $87.81 | 2023-2024 | Trintellix |
| Eisai INC. | $71.14 | 2024 | |
| Verona Pharma, INC. | $49.05 | 2025 | Ohtuvayre |
| Esperion Therapeutics, INC. | $46.01 | 2023-2024 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $44.21 | 2025 | Azstarys |
| Pfizer INC. | $39.45 | 2024 | |
| Acella Pharmaceuticals, LLC | $25.67 | 2024 | NP Thyroid 60 |
| Dexcom, INC. | $24.42 | 2024 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $23.40 | 2024 | Nuzyra |
| Glaxosmithkline, LLC. | $23.12 | 2024 | Trelegy Ellipta, Arexvy |
| Shield Therapeutics INC | $20.63 | 2024 | |
| Corcept Therapeutics | $19.81 | 2025 | Korlym |
| Viatris Specialty LLC | $19.55 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $19.11 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $16.33 | 2024 | Voquezna |
| Tolmar, INC. | $15.75 | 2025 | Jatenzo |
| Radius Health, INC. | $15.31 | 2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $14.58 | 2023 | Seglentis, Livalo |
| Azurity Pharmaceuticals, INC. | $13.07 | 2023 | Horizant |
| Currax Pharmaceuticals LLC | $12.72 | 2023 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Timmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.